Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

NYSE - Nasdaq Real Time Price USD

Bio-Rad Laboratories, Inc. (BIO-B)

Compare

312.05

0.00

(0.00%)

As of February 13 at 10:34:33 AM EST. Market Open.

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks 3 hours ago

VCYT

CAH

RMD
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.

Zacks 4 days ago

GMED

RMD

CAH
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.

Zacks 5 days ago

EXAS

RMD

CAH
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks 6 days ago

PEN

RMD

CAH
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.

Zacks 7 days ago

MDT

RMD

CAH
BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Zacks 7 days ago

BIO-B
0.00%
RMD
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 8 days ago

BIO-B
0.00%
Bio-Rad price target lowered to $447 from $477 at RBC Capital

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company reported a slight miss for Q4, with guidance coming in below consensus estimates on the top and bottom line, though based on peers’ results thus far, the low-single-digit top-line guide is not a major surprise, the analyst tells investors in a research note. RBC adds however that the lack of meaningful margin expansion by Bio-Rad was still surprising. Published

TipRanks 10 days ago

BIO

BIO-B
0.00%
Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Bio-Rad Laboratories ( NYSE:BIO ) Full Year 2024 Results Key Financial Results Revenue: US$2.57b (down 3.9% from FY...

Simply Wall St. 10 days ago

BIO

BIO-B
0.00%
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

Zacks 10 days ago

BIO-B
0.00%
DGX

CAH
Bio-Rad set to acquire Stilla Technologies

Pending consultations and regulatory approval necessitates, the deal is expected to close by Q3 2025.

Medical Device Network 10 days ago

BIO-B
0.00%
Q4 2024 Bio Rad Laboratories Inc Earnings Call

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Thomson Reuters StreetEvents 11 days ago

BIO-B
0.00%
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks 11 days ago

BRKR

RMD

CAH
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Despite a decline in net sales, Bio-Rad Laboratories Inc (BIO) achieved gross margin expansion and improved free cash flow, while setting the stage for future growth with strategic acquisitions.

GuruFocus.com 11 days ago

BIO-B
0.00%
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of -1.02% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 days ago

BIO-B
0.00%
Bio-Rad: Q4 Earnings Snapshot

BIO.B) on Thursday reported a fourth-quarter loss of $715.8 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Hercules, California-based company said it had a loss of $25.57. Earnings, adjusted for one-time gains and costs, were $2.90 per share.

Associated Press Finance 11 days ago

BIO-B
0.00%
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

HERCULES, Calif., February 13, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire 11 days ago

BIO

BIO-B
0.00%
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

HERCULES, Calif., February 13, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies ("Stilla"). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quar

Business Wire 11 days ago

BIO

BIO-B
0.00%
CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

CVS tops earnings and revenue estimates in the fourth quarter of 2024 amid macroeconomic impacts in the Health Care Benefits arm.

Zacks 13 days ago

CVS

RMD

CAH
OncoCyte prices $29.1M equity offering

Oncocyte (OCX) has entered into securities purchase agreements with existing investors for a registered direct offering and concurrent private placement. The Company’s five largest shareholders, including Bio-Rad (BIO) Laboratories, led the funding round. The round is expected to result in gross cash proceeds to the Company totaling $29.1M priced at $2.05 per share. Two members of the Company’s management team also participated in the private placement. In addition to its equity investment, Bio-

TipRanks 14 days ago

BIO

BIO-B
0.00%
OCX

Performance Overview

Return	BIO-B	S&P 500
YTD	-4.16%	+1.00%
1-Year	-7.68%	+16.74%
3-Year	-51.67%	+35.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bio-Rad Laboratories, Inc. (BIO-B)

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Bio-Rad: Q4 Earnings Snapshot

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

OncoCyte prices $29.1M equity offering

Performance Overview